Radiation plus dostarlimab for post-surgery endometrial cancer
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This Phase 2 study tests whether adding dostarlimab (an immunotherapy medicine) to radiation after surgery can lower cancer returning and improve outcomes. It’s for people with certain endometrial cancers found to have specific genetic/molecular changes and who have stage III/IVA disease after surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older
- Your cancer is endometrial cancer, and you had full surgical staging showing stage III or stage IVA disease
- Your tumor has one of these: MMR-D, MSI-H, or POLE mutation (tumor testing reports are needed, unless POLE was tested outside the hospital)
- After surgery, you must NOT have measurable remaining disease on imaging (according to RECIST 1.1)
- You must have finished surgery 3 to 12 weeks before starting treatment and be well enough to proceed
- You must have blood test and organ-function levels that meet study limits (including enough white blood cells, platelets, kidney function, and liver enzymes)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study tests whether giving a short course of radiation together with chemotherapy can help treat endometrial cancer after surgery. It aims to find a treatment plan that is effective while keeping side effects manageable.
This trial tests whether giving a drug called dostarlimab (an immunotherapy that boosts your immune system to fight cancer) before and after surgery can help treat advanced endometrial cancer. It is for people with stage 3 or 4 endometrial cancer who haven't had treatment yet and may be eligible if their tumor has a specific marker called mismatch repair deficiency.
This Phase 1 trial studies how safe and tolerable it is to add dostarlimab (an immunotherapy) to standard chemo and radiation, followed by more chemotherapy, for stage IIIC endometrial cancer that has spread to lymph nodes. It aims to see whether this combination can be given safely soon after surgery.
This trial tests whether an immunotherapy combination can help shrink or control endometrial cancer so that surgery might not be needed. It is for people whose tumors have a specific genetic feature (dMMR/MSI-H) that may respond well to this treatment.
This Phase 2 trial studies dostarlimab (an immune therapy that targets PD-1) given before surgery or other initial treatment. It aims to shrink certain locally advanced cancers that have mismatch repair deficiency, potentially making treatment easier and improving outcomes.
This trial tests whether giving the drug dostarlimab before surgery can shrink or control endometrial cancer. It is for people whose tumors have a specific genetic feature (MMR deficiency) that may make the drug more effective.
Hear when a new Endometrial Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.